Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

View Cancer Clinical Trials

ARRY 162311   |   13-1209
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.)

Disease(s)
Fallopian Tube
Gynecologic
Ovarian
Peritoneal
Hospital(s)
Fairview
Hillcrest
Main Campus
Phase(s)
Phase 3
Stage(s)
Recurrent/Relapsed
Type(s)
Drug(s)

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description
Trial Description Not Available

Inclusion Criteria
Inclusion Criteria Not Available

Exclusion Criteria
Exclusion Criteria Not Available

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.